This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / SynSmart, Amporin Collaborate on Therapeutics
Business collaboration agreement

SynSmart, Amporin Collaborate on Therapeutics

Analysis based on 7 articles · First reported Apr 19, 2026 · Last updated Apr 20, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The collaboration between SynSmart Rasayan Research Private Limited and Amporin Pharmaceuticals AG is expected to positively impact the biotechnology and pharmaceutical markets by accelerating the development of new treatments for degenerative diseases. This could lead to increased investment and innovation in the sector, potentially benefiting both companies and the broader market.

Biotechnology Pharmaceuticals
Event Summary

SynSmart Rasayan Research Private Limited and Amporin Pharmaceuticals AG announced a collaboration to develop breakthrough small molecule therapeutics for deadly degenerative diseases. Under the agreement, SynSmart Rasayan Research Private Limited will synthesize a library of novel membrane-protecting molecules at its Mumbai facility. The collaboration aims to accelerate the project to candidate selection, with potential extensions into follow-on chemistry and ADME-PK areas. Saurabh Kapure, CEO of SynSmart Rasayan Research Private Limited, highlighted the value SynSmart Rasayan Research Private Limited brings, while Kelvin Stott, CEO of Amporin Pharmaceuticals AG, expressed excitement about accelerating disease-modifying treatments and validating their asset platform.

Entities Involved
priv
SynSmart Rasayan Research Private Limited
SynSmart Rasayan Research Private Limited entered into a collaboration with Amporin Pharmaceuticals AG to develop small molecule therapeutics, which is expected to accelerate its growth and market presence.
Importance 90.0 Sentiment 70.0
priv
Amporin Pharmaceuticals AG
Amporin Pharmaceuticals AG collaborated with SynSmart Rasayan Research Private Limited to accelerate the development of disease-modifying treatments for degenerative diseases, validating its unique asset platform.
Importance 90.0 Sentiment 70.0
per
Saurabh Kapure
Saurabh Kapure, CEO at SynSmart Rasayan Research Private Limited, commented on the collaboration, highlighting the value SynSmart Rasayan Research Private Limited brings to its partners.
Importance 30.0 Sentiment 0.0
per
Kelvin Stott
Kelvin Stott, Founder and CEO at Amporin Pharmaceuticals AG, expressed excitement about the collaboration, emphasizing its potential to accelerate drug development.
Importance 30.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.